Comparing ketorolac and cortisone injections for knee osteoarthritis
Triamcinolone Ketorolac (TriKe) Knee Trial Evaluating the Effectiveness and Possible Superiority of Ketorolac vs. Cortisone When Injected Intra-Articular in Subjects With Osteoarthrosis
This study tests whether a new knee injection with ketorolac can help people with osteoarthritis feel less pain and move better compared to cortisone injections.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | United Health Services Hospitals, Inc. Academic / other |
| Locations | 1 site (Vestal, New York) |
| Trial ID | NCT05336968 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of intra-articular ketorolac compared to cortisone injections for treating knee osteoarthritis. Participants will receive either ketorolac, cortisone, or a combination of both as a one-time injection into the affected knee joint. The study will assess pain relief and functional improvement through surveys administered before the injection and at multiple follow-up points. The goal is to determine if ketorolac can provide similar or better outcomes than cortisone while minimizing adverse effects.
Who should consider this trial
Good fit: Ideal candidates are adults over 21 with knee pain diagnosed as osteoarthritis and who can complete follow-up surveys.
Not a fit: Patients with recent knee injections, uncontrolled diabetes, or contraindications to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a safer and more effective treatment option for patients with knee osteoarthritis.
How similar studies have performed: While there is increasing interest in using ketorolac for intra-articular injections, limited data exists comparing it directly with cortisone in randomized trials, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Knee pain with diagnosis of osteoarthritis/osteoarthrosis * Weight-bearing x-rays within the last year adequate to assess Kellgran-Lawrence OA stage * Age \> 21 * English proficiency sufficient to complete surveys * Willing to complete follow-up surveys Exclusion Criteria: * Prior knee injection in last 3 months * Knee surgery within the last year * Contraindications to Cortisone, Ketorolac, or local anesthetic * Uncontrolled diabetes * Systemic steroid use in last 3 months * BMI \> 50 * Non-ambulatory * Known kidney disease * Current opioid use
Where this trial is running
Vestal, New York
- United Health Services Sports Medicine Department — Vestal, New York, United States (Recruiting)
Study contacts
- Principal investigator: Stanley Hunter, MD — United Health Services Hospitals, Inc.
- Study coordinator: Terri Peters, RN MSN CCRP
- Email: terri.peters@nyuhs.org
- Phone: 607-763-5697
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.